Vaccine for prevention and treatment of Trypanosoma Cruzi infection (CRUZIVAX)
A new vaccine for the killer disease Chagas
Vector-borne diseases, spread by organisms such as pathogen-carrying insects, account for more than 17 % of all infectious diseases and they disproportionately affect people in the poorest populations. One of those is Chagas disease, prevalent mainly in Latin American countries. In severe cases, Chagas disease can cause congestive heart failure and cardiac arrest. CRUZIVAX is taking a needle-free vaccine candidate from preclinical trials in mice through to a Phase I clinical trial in healthy volunteers. Even better, the study includes low-cost manufacturing and a health economics analysis to support widespread access by healthcare systems in poor countries that are the most vulnerable.
Learn more about iBET participation in this project here.